Obesity and non adherence correlate with elevated serum estradiol levels in postmenopausal women receiving adjuvant aromatase inhibitor therapy

Breast Journal

Volumn 20, Issue 5, 2014, Pages 553-554

  Decker, David A ^a   Reynolds, Robert B ^a   Molthrop, David C ^a   Griffith, Elizabeth ^a   Encarnacion, Tiffany ^a   Lee, Eimon ^b   Zhu, Xiang ^a  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; EXEMESTANE; LETROZOLE;

ADJUVANT THERAPY; ADULT; AGED; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER SURVIVOR; CLINICAL ARTICLE; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; LETTER; MEDICATION COMPLIANCE; OBESITY; POSTMENOPAUSE; SECONDARY PREVENTION; SURVIVOR; TREATMENT REFUSAL; BLOOD; BREAST NEOPLASMS; COMPLICATION; MIDDLE AGED; PATIENT COMPLIANCE; UNITED STATES;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FLORIDA; HUMANS; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; POSTMENOPAUSE;

EID: 84908143756     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12324     Document Type: Letter

References (8)

1. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
2. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-41.
3. Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993;53:266-70.
4. Wills S, Ravipati A, Venuturumilli P, et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012;8:144-8.
5. Nagao T, Kira M, Takahashi M, et al. Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. World J Surg Oncol 2009;7:88.
6. Folkerd EJ, Dixon JM, Renshaw L, et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 2012;30:2977-80.
7. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:627-35.
8. Kwan ML, Chen WY, Kroenke CH, et al. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2012;132:729-39.